298 related articles for article (PubMed ID: 31504702)
1. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
[TBL] [Abstract][Full Text] [Related]
3. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
[TBL] [Abstract][Full Text] [Related]
4. Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
Sho T; Suda G; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Izumi T; Kawagishi N; Baba M; Nakai M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
Intern Med; 2019 Mar; 58(6):797-802. PubMed ID: 30449808
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Rockstroh JK; Lacombe K; Viani RM; Orkin C; Wyles D; Luetkemeyer AF; Soto-Malave R; Flisiak R; Bhagani S; Sherman KE; Shimonova T; Ruane P; Sasadeusz J; Slim J; Zhang Z; Samanta S; Ng TI; Gulati A; Kosloski MP; Shulman NS; Trinh R; Sulkowski M
Clin Infect Dis; 2018 Sep; 67(7):1010-1017. PubMed ID: 29566246
[TBL] [Abstract][Full Text] [Related]
6. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
Mensa FJ; Lovell S; Pilot-Matias T; Liu W
Future Microbiol; 2019 Jan; 14():89-110. PubMed ID: 30499343
[TBL] [Abstract][Full Text] [Related]
7. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
Huff J; Andersen R
Ann Pharmacother; 2020 Mar; 54(3):262-276. PubMed ID: 31537106
[No Abstract] [Full Text] [Related]
8. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
[TBL] [Abstract][Full Text] [Related]
10. No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Kosloski MP; Zhao W; Asatryan A; Kort J; Geoffroy P; Liu W
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28807904
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
Lin CW; Dutta S; Zhao W; Asatryan A; Campbell A; Liu W
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):81-90. PubMed ID: 28688001
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.
Jonas MM; Squires RH; Rhee SM; Lin CW; Bessho K; Feiterna-Sperling C; Hierro L; Kelly D; Ling SC; Strokova T; Del Valle-Segarra A; Lovell S; Liu W; Ng TI; Porcalla A; Gonzalez YS; Burroughs M; Sokal E
Hepatology; 2020 Feb; 71(2):456-462. PubMed ID: 31254392
[TBL] [Abstract][Full Text] [Related]
15. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
16. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
El-Sherif O; Khoo S; Solas C
Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
[TBL] [Abstract][Full Text] [Related]
17. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
Hubbard H; Lawitz E
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
[TBL] [Abstract][Full Text] [Related]
18. Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.
Kosloski MP; Zhao W; Li H; Pugatch D; Asatryan A; Kort J; Mensa FJ; Liu W
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):779-789. PubMed ID: 30861340
[TBL] [Abstract][Full Text] [Related]
19. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
[TBL] [Abstract][Full Text] [Related]
20. Glecaprevir + pibrentasvir for treatment of hepatitis C.
Carrion AF; Martin P
Expert Opin Pharmacother; 2018 Mar; 19(4):413-419. PubMed ID: 29465262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
